Sajeev K Puri1, Lingbao Si, Chun-Yang Fan, Ehab Hanna. 1. Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. purisajeevk@uams.edu
Abstract
PURPOSE: Epigenetic alteration, via promoter hypermethylation, inactivates genes important for the development of head and neck squamous cell carcinoma (SCCHN). The aim of this study is to characterize and correlate, with clinical parameters, the promoter methylation profile of DNA repair genes, hMLH1 and O6-methylguanine-DNA methyltransferase (MGMT), and tumor-suppressor gene p16. MATERIALS AND METHODS: Fifty-one cases of SCCHN, collected from the paraffin block archives (1997-1999) in the Department of Pathology at the University of Arkansas for medical sciences, provided DNA for methylation-specific PCR using primers specific for hMLH1, MGMT, and p16. RESULTS: Sixty-two percent displayed promoter hypermethylation in at least one gene, with 23% seen for hMLH1, 30% for MGMT, and 36% for p16. Promoter hypermethylation of these genes separately or in combination was not associated with history of smoking and alcohol use, tumor size, nodal status, clinical stage, and overall survival. Promoter hypermethylation of more than 1 gene was significantly associated with increased 2-year disease-free survival. The probability of surviving 2 years without tumor recurrence was 100% with promoter hypermethylation in 2 or 3 genes and 46% with promoter hypermethylation in none or just 1 gene (P=.013). Promoter hypermethylation of 2 or 3 genes was independently related to increased 2-year cumulative disease-free survival (P=.028). CONCLUSIONS: Promoter hypermethylation of hMLH1, MGMT, and p16 genes was commonly detected in 47 SCCHN cases with up to 65% showing aberrant promoter hypermethylation in at least 1 gene. Promoter hypermethylation of 2 or 3 genes was significantly associated with increased 2-year disease-free survival, suggesting that promoter hypermethylation of multiple genes might improve survival. Significant correlation was also noted between a positive alcohol use history and promoter hypermethylation of the MGMT gene with no promoter hypermethylation of the p16 gene.
PURPOSE: Epigenetic alteration, via promoter hypermethylation, inactivates genes important for the development of head and neck squamous cell carcinoma (SCCHN). The aim of this study is to characterize and correlate, with clinical parameters, the promoter methylation profile of DNA repair genes, hMLH1 and O6-methylguanine-DNA methyltransferase (MGMT), and tumor-suppressor gene p16. MATERIALS AND METHODS: Fifty-one cases of SCCHN, collected from the paraffin block archives (1997-1999) in the Department of Pathology at the University of Arkansas for medical sciences, provided DNA for methylation-specific PCR using primers specific for hMLH1, MGMT, and p16. RESULTS: Sixty-two percent displayed promoter hypermethylation in at least one gene, with 23% seen for hMLH1, 30% for MGMT, and 36% for p16. Promoter hypermethylation of these genes separately or in combination was not associated with history of smoking and alcohol use, tumor size, nodal status, clinical stage, and overall survival. Promoter hypermethylation of more than 1 gene was significantly associated with increased 2-year disease-free survival. The probability of surviving 2 years without tumor recurrence was 100% with promoter hypermethylation in 2 or 3 genes and 46% with promoter hypermethylation in none or just 1 gene (P=.013). Promoter hypermethylation of 2 or 3 genes was independently related to increased 2-year cumulative disease-free survival (P=.028). CONCLUSIONS: Promoter hypermethylation of hMLH1, MGMT, and p16 genes was commonly detected in 47 SCCHN cases with up to 65% showing aberrant promoter hypermethylation in at least 1 gene. Promoter hypermethylation of 2 or 3 genes was significantly associated with increased 2-year disease-free survival, suggesting that promoter hypermethylation of multiple genes might improve survival. Significant correlation was also noted between a positive alcohol use history and promoter hypermethylation of the MGMT gene with no promoter hypermethylation of the p16 gene.
Authors: Samson Mani; Katarzyna Szymańska; Cyrille Cuenin; David Zaridze; Karen Balassiano; Sheila C S Lima; Elena Matos; Alexander Daudt; Sergio Koifman; Victor Wunsch Filho; Ana M B Menezes; Maria Paula Curado; Gilles Ferro; Thomas Vaissière; Bakary S Sylla; Massimo Tommasino; Luis Felipe Ribeiro Pinto; Paolo Boffetta; Pierre Hainaut; Paul Brennan; Zdenko Herceg Journal: Epigenetics Date: 2012-03 Impact factor: 4.528
Authors: Graham M Poage; Rondi A Butler; E Andrés Houseman; Michael D McClean; Heather H Nelson; Brock C Christensen; Carmen J Marsit; Karl T Kelsey Journal: Cancer Res Date: 2012-04-16 Impact factor: 12.701
Authors: Meng Hua Tao; Catalin Marian; Peter G Shields; Jing Nie; Susan E McCann; Amy Millen; Christine Ambrosone; Alan Hutson; Stephen B Edge; Shiva S Krishnan; Bin Xie; Janet Winston; Dominica Vito; Marcia Russell; Thomas H Nochajski; Maurizio Trevisan; Jo L Freudenheim Journal: Alcohol Date: 2010-12-18 Impact factor: 2.405
Authors: L J Melchers; M J A M Clausen; M F Mastik; L Slagter-Menkema; J E van der Wal; G B A Wisman; J L N Roodenburg; E Schuuring Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Emanuela Taioli; Camille Ragin; Xiao-Hong Wang; Jiangying Chen; Scott M Langevin; Ashley R Brown; Susanne M Gollin; Seymour Garte; Robert W Sobol Journal: BMC Cancer Date: 2009-10-06 Impact factor: 4.430